YD Bio

YD Bio FCF per Share

The Free Cash Flow per Share of YD Bio (YDES) as of Oct 16, 2026 is -0.11 USD. In the previous year, Free Cash Flow per Share was -1.18 USD — a change of -90.32% (higher).

FCF per Share

-0.11USD

YoY

-90.32%

Last updated:

Free Cash Flow per Share of YD Bio is 2025 -0.11 USD. Free Cash Flow per Share of YD Bio was 2024 -1.18 USD. It decreases by -90.32% higher compared to the previous year.

The YD Bio FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.01 USD
Jan 1, 2022
-0.04 USD
Jan 1, 2023
-0.01 USD
Jan 1, 2024
-1.18 USD
Jan 1, 2025
-0.11 USD
The YD Bio FCF per Share history
YEARFCF per ShareYoY
-0.11USD-90.32%
-1.18USD+8,945.05%
-0.01USD-69.50%
-0.04USD+339.08%
-0.01USD+171.43%
-0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

Free Cash Flow per Share of YD Bio is -0.11 USD in 2025.

Free Cash Flow per Share of YD Bio changed from -1.18 USD to -0.11 USD, representing a -90.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share YD Bio since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — YD Bio

All Key Metrics — YD Bio